Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Washington Post National Health Reporter Paige Winfield Cunningham discusses how the Trump administration is considering ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Donald Trump appears to be working on lowering the costs of medications, but just below the surface, his efforts on drug ...

The Trump administration is considering a shift in health care coverage, allowing Medicare and Medicaid to cover GLP-1 weight ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

The Trump administration is expanding its data push, reaching into domains long controlled by the states — and further into ...